Precigen, Inc. (PGEN) Misses Q2 EPS by 13c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Precigen, Inc. (PGEN) Misses Q2 EPS by 13c, Revenues Beat

Precigen, Inc. (PGEN) Reports Phase 1b Study of AG019 ActoBiotics Met Primary Endpoint Assessing Safety and Tolerability

August 10, 2020 7:36 AM EDT

Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. (NASDAQ: PGEN), today announced it has met the primary endpoint assessing safety and tolerability in the Phase 1b monotherapy portion of the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics for the treatment of early-onset type 1 diabetes (T1D) (clinical trial identifier:... More

Precigen, Inc. (PGEN) Provides Six-month Follow-up Data from Phase I Study of INXN-4001

August 6, 2020 7:54 AM EDT

Precigen Triple-Gene, a clinical stage cardiovascular gene therapy company and majority-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced six-month follow-up data from the Phase I trial of INXN-4001 (clinical trial identifier: NCT03409627), a multigenic investigational therapeutic candidate under evaluation for the treatment of heart failure.... More